Novartis readies first smart pill app

After investing $24 million earlier this year to gain access to cutting-edge smart pill technology, Novartis ($NVS) says it is 18 months away from filing for approval of its first chip-in-a-pill offering. The chips broadcast information to a skin patch, which in turn relays the information via smart phone. The first application will center on proper dosing for an approved drug that is used to prevent organ rejection among transplant patients. And because it is an existing drug, Novartis says that it only needs to prove bioequivalency rather than sponsor new clinical trials. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.